Dova pharmaceuticals inc. (DOVA)
Income statement / Quarterly
Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16
Revenue
Revenue

3,373

3,516

4,001

2,842

2,929

4,584

0

-

-

-

-

-

-

-

Operating expenses:
Cost of product sales

653

444

515

291

370

519

0

-

-

-

-

-

-

-

Research and development

4,188

4,505

4,084

5,533

4,847

4,508

3,416

2,714

5,426

3,293

4,276

6,944

6,758

6,990

Selling, general and administrative

-

-

-

16,064

-

-

-

6,454

4,185

1,905

955

-

-

-

Selling, general and administrative

19,197

15,496

15,754

-

17,031

18,565

10,261

-

-

-

-

558

368

263

Total operating expenses

24,038

20,445

20,353

21,888

22,248

23,592

13,677

9,168

9,611

5,198

5,231

7,502

7,126

7,253

Loss from operations

-20,665

-16,929

-16,352

-19,046

-19,319

-19,008

-13,677

-9,168

-9,611

-5,198

-5,231

-7,502

-7,126

-7,253

Interest income and other income (expense), net

235

439

537

275

342

-195

222

243

224

-14

33

18

-10

-

Interest expense - related party

-

-

-

-

-

-

-

-

-

-

-

1

3

1

Interest expense

855

574

564

561

546

454

315

375

336

295

226

115

35

-

Total other expenses, net

-620

-135

-27

-286

-204

-649

-93

-132

-112

-309

-193

-98

-48

-1

Interest income and other income (expense), net

235

439

537

275

342

-195

222

243

224

-14

33

-

-

-

Net loss

-21,285

-17,064

-16,379

-19,332

-19,523

-19,657

-13,770

-9,300

-9,723

-5,507

-5,424

-7,600

-7,174

-7,254

Net loss per share, basic and diluted (in dollars per share)

-0.74

-0.60

-0.58

-0.69

-0.69

-0.70

-0.52

-0.36

-0.38

-0.32

-0.31

-0.44

-0.41

-0.42

Weighted average common shares outstanding, basic and diluted (in shares)

28,799

28,291

28,221

28,204

28,203

28,194

26,589

25,652

25,290

17,332

17,332

17,332

17,332

17,332

Product sales, net
Revenue

1,453

3,516

4,001

2,842

2,929

1,957

0

-

-

-

-

-

-

-

Other revenue
Revenue

1,920

0

-

0

0

2,627

-

-

-

-

-

-

-

-